# A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

> **NCT03809767** · PHASE1 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 107 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** CS1003 monoclonal antibody

## Key facts

- **NCT ID:** NCT03809767
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-29
- **Primary completion:** 2021-08-30
- **Final completion:** 2022-06-13
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03809767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03809767, "A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03809767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*